Hemoglobin Level Increase as an Efficacy Biomarker During Axitinib Treatment for Metastatic Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Haemoglobin Level Increase as an Efficacy Biomarker During Axitinib Treatment for Metastatic Renal Cell Carcinoma: A Retrospective Study
BMC Cancer 2017 May 22;[EPub Ahead of Print], AC Johnson, M Matias, H Boyle, B Escudier, A Molinier, B Laguerre, C Helissey, PE Brachet, AE Dugué, L Mourey, E Coquan, F JolyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.